Show simple item record

dc.contributor.authorAkar, Remzi Okan
dc.contributor.authorSelvi, Selin
dc.contributor.authorUlukaya, Engin
dc.contributor.authorAztopal, Nazlihan
dc.date.accessioned2020-08-30T20:07:07Z
dc.date.available2020-08-30T20:07:07Z
dc.date.issued2019
dc.identifier.citationAkar, R. O., Selvi, S., Ulukaya, E., & Aztopal, N. (2019). Key actors in cancer therapy: epigenetic modifiers. Turkish Journal of Biology, 43(3), 155-170.en_US
dc.identifier.issn1300-0152
dc.identifier.issn1303-6092
dc.identifier.urihttps://doi.org/10.3906/biy-1903-39
dc.identifier.urihttps://hdl.handle.net/20.500.12713/697
dc.descriptionAZTOPAL, NAZLIHAN/0000-0003-3118-8061; AKAR, Okan/0000-0001-8687-2034; Ulukaya, Engin/0000-0003-4875-5472en_US
dc.descriptionWOS: 000471268100001en_US
dc.descriptionPubMed: 31320814en_US
dc.description.abstractEpigenetic reprogramming plays a crucial role in the tumorigenicity and maintenance of tumor-specific gene expression that especially occurs through DNA methylation and/or histone modifications. It has well-defined mechanisms. It is known that alterations in the DNA methylation pattern and/or the loss of specific histone acetylation/methylation markers are related to several hallmarks of cancer, such as drug resistance, sternness, epithelial-mesenchymal transition, and metastasis. It has also recently been highlighted that epigenetic alterations are critical for the regulation of the stemlike properties of cancer cells (tumor-initiating cells; cancer stem cells). Cancer stem cells are thought to be responsible for the recurrence of cancer which makes the patient return to the clinic with metastatic tumor tissue. Hence, the dysregulation of epigenetic machinery represents potential new therapeutic targets. Therefore, compounds with epigenetic activities have become crucial for developing new therapy regimens (e.g., antimetastatic agents) in the fight against cancer. Here, we review the epigenetic modifiers that have already been used in the clinic and/or in clinical trials, related preclinical studies in cancer therapy, and the smart combination strategies that target cancer stem cells along with the other cancer cells. The emerging role of epitranscriptome (RNA epigenetic) in cancer therapy has also been included in this review as a new avenue and potential target for the better management of cancer-beneficial epigenetic machinery.en_US
dc.language.isoengen_US
dc.publisherTubitak Scientific & Technical Research Council Turkeyen_US
dc.relation.isversionof10.3906/biy-1903-39en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectEpigenetic Modificationsen_US
dc.subjectRna Epigeneticen_US
dc.subjectAnticancer Drugsen_US
dc.subjectCancer Stem Cellsen_US
dc.titleKey actors in cancer therapy: epigenetic modifiersen_US
dc.typereviewen_US
dc.contributor.departmentİstinye Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümüen_US
dc.contributor.authorID0000-0001-8687-2034en_US
dc.contributor.authorID0000-0003-4875-5472en_US
dc.contributor.authorID0000-0003-3118-8061en_US
dc.contributor.institutionauthorAkar, Remzi Okanen_US
dc.contributor.institutionauthorSelvi, Selinen_US
dc.contributor.institutionauthorUlukaya, Enginen_US
dc.contributor.institutionauthorAztopal, Nazlihanen_US
dc.identifier.volume43en_US
dc.identifier.issue3en_US
dc.identifier.startpage155en_US
dc.identifier.endpage170en_US
dc.relation.journalTurkish Journal of Biologyen_US
dc.relation.publicationcategoryDiğeren_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record